Paolo Strati

Paolo Strati, MD

The University of Texas MD Anderson Cancer Center

Session Chair

Biography

Paolo Strati MD is currently an Associate Professor, with Term Tenure, Deputy Section Chief for Indolent B-cell Lymphomas, Fellowship Director and CARTOX Program Leader in the Department of Lymphoma and Myeloma with a joint appointment in the Department of Translational Molecular Pathology, at the University of Texas MD Anderson Cancer Center, in Houston, TX. He previously served as Assistant Professor at the Mayo Clinic, in Rochester (MN). Dr. Strati earned his medical degree cum laude from the San Raffaele University of Milan (Italy) in 2008, and completed an Internal Medicine Residency at the same institution and, subsequently, at the Mayo Clinic, in Rochester (MN). He also completed a Hematology-Oncology Fellowship at MD Anderson Cancer Center, a Leukemia and Lymphoma fellowship at the same institution, and a Malignant Hematology fellowship at the Barts Cancer Institute, in London (UK). Dr. Strati is a recognized expert in the field of immunotherapy and cellular therapy for the treatment of B-cell lymphoma, and he is the principal investigator of multiple clinical trials and translational projects related to this topic. He is author of several peer-reviewed manuscripts published on high impact journal, including Blood and Lancet Haematology, and he is regularly invited to present his work at international scientific meetings, including the American Society of Hematology and the American Society of Clinical Oncology conference. In light of his research accomplishments, he has received multiple grants and awards, including a NIH R21 grant, the Lymphoma Research Foundation Career Development Award and the Leukemia Lymphoma Society Career Development Award. Dr. Strati is committed to gain further insight into the biology of the lymphoma immune microenvironment, and to manipulate its components successfully, in order to develop novel effective therapies and to decrease the toxicity of treatment strategies already available for patients with B-cell lymphoma.

Financial Disclosure

Astrazeneca

Advisor

Ipsen

Advisor

Incyte

Advisor

Beigene

Advisor

ADC Therapeutics

Advisor

Kite-Gilead

Advisor

Roche Genentech

Consultant

Genmab Abbvie

Consultant

Lilly

Advisor

Novartis

Advisor

ALX Oncology

Researcher